In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von María-Alexandra Cañas und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus aureus, Staphylococcus, Endocarditis, Bacterial. Die Arbeit nennt 31 Literaturangaben. Gefördert von: ContraFec, Spanish Network for Research in Infectious Diseases, REIPI.
Abstract (Originalsprache)
Background
Infective endocarditis (IE) is a severe infection mainly caused by Staphylococcus aureus, Enterococcus faecalis and viridans streptococci. Coagulase-negative staphylococci (CoNS), especially methicillin-resistant Staphylococcus epidermidis (MRSE), are major pathogens in prosthetic valves and devices. Exebacase is a first-in-class, antistaphylococcal lysin with rapid bactericidal and antibiofilm activity.
Objective
To assess the in vitro activity of exebacase and standard IE antibiotics against S. aureus and CoNS isolates from IE patients in a university hospital (2010–2020).
Methods
A total of 211 consecutive strains were analysed: S. aureus [n = 103 (82 MSSA, 21 MRSA)], S. epidermidis [n = 76 (20 MSSE, 56 MRSE)] and other CoNS species (n = 32, Staphylococcus haemolyticus, Staphylococcus lugdunensis, Staphylococcus hominis, Staphylococcus capitis, Staphylococcus schleiferi, Staphylococcus caprae, Staphylococcus pasteuri). Broth microdilution MICs were determined for exebacase and comparators (cloxacillin, ceftaroline, vancomycin, daptomycin, gentamicin, rifampicin).
Results
Exebacase inhibited all S. aureus at ≤1 mg/L. Geometric mean (GM) MICs were 0.56 mg/L for MSSA and 0.49 mg/L for MRSA, with MIC50/90 of 0.5/1 mg/L. For S. epidermidis, GM MICs were 3.03 mg/L (MSSE) and 3.40 mg/L (MRSE), with MIC50/90 of 4/16 and 4/8 mg/L, respectively. Other CoNS showed GM MICs ranging from 0.49 mg/L (S. capitis) to 2.59 mg/L (S. lugdunensis), with intermediate values for S. haemolyticus (1.15), S. hominis (1.0) and S. schleiferi (0.79). Exebacase activity was comparable to β-lactams, vancomycin and daptomycin and remained unaffected by resistance.
Conclusions
Exebacase activity was independent of methicillin resistance and consistently higher against S. aureus than S. epidermidis. Further research is warranted to explore lysins in combination against staphylococcal infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
- CIBER Thematic Area of Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Madrid, Spain.
- Microbiology, Genetics and Statistics Department, University of Barcelona, Barcelona, Spain.
- ContraFect Corporation, Yonkers, NY, USA.
- Reial Academia de Medicina de Catalunya, Barcelona, Spain.
ORCID-Profile: María-Alexandra Cañas, Guillermo Cuervo, Cristina García-De-La-Mària, José M Miró
Förderung
- ContraFec
- Spanish Network for Research in Infectious Diseases
- REIPI
- Sara Borrell personal research
- Instituto de Salud Carlos III
- Pla estratègic de recerca i innovació en salut
- Juan Rodés Research
- Ministerio de Economia y Competitividad, Madrid
Zitieren
APA
Cañas, M. A., Cuervo, G., García-González, J., Krivak, F., Hernández-Meneses, M., Falces, C., Perissinotti, A., Vidal, B., Tolosana, J. M., Sandoval, E., Quintana, E., Llopis, J., Moreno, A., Schuch, R., García-De-La-Mària, C., & Miró, J. M. (2026). In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf435
Vancouver
Cañas MA, Cuervo G, García-González J, Krivak F, Hernández-Meneses M, Falces C, et al. In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf435
BibTeX
@article{Caas2026,
author = {Cañas, María-Alexandra and Cuervo, Guillermo and García-González, Javier and Krivak, Filip and Hernández-Meneses, Marta and Falces, Carles and Perissinotti, Andres and Vidal, Barbara and Tolosana, José María and Sandoval, Elena and Quintana, Eduard and Llopis, Jaume and Moreno, Asunción and Schuch, Raymond and García-De-La-Mària, Cristina and Miró, José M},
title = {In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf435}
}
EUVIMED